PTC-209 (hydrobromide)
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs) . PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment[1][2].
Product Specifications
CAS Number
1217022-63-3
UNSPSC
12352005
Target
Autophagy; BMI1
Type
Reference compound
Related Pathways
Autophagy; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PTC-209-hydrobromide.html
Purity
99.02
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(C2=CSC(NC3=C(Br)C=C(OC)C=C3Br)=N2)N4C=CC=NC4=N1.Br
Molecular Formula
C17H14Br3N5OS
Molecular Weight
576.10
References & Citations
[1]Kreso A, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20 (1) :29-36.|[2]Christian Mayr, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016 Jan 5; 7 (1) : 745-758.|[3]Shahi MH, et al. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance. PLoS One. 2015 Jun 25;10 (6) :e0131006.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K7219007 1.0 µg DNA
Cant1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)
Sign In for Pricing
View Details